Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RLYB Rallybio Corp.

Not Yet Opened 12-10 16:00:00 EST

0.7700

+0.0473

+6.54%

盘后0.7800

+0.0100+1.30%

17:28 EST

High0.8000	Low0.7228	Vol415.10K
Open0.7250	D1 Closing0.7227	Amplitude10.68%
Mkt Cap32.53M	Tradable Cap15.64M	Total Shares42.24M
T/O323.17K	T/O Rate2.04%	Tradable Shares20.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RLYB","market":"US","secType":"STK","nameCN":"Rallybio Corp.","latestPrice":0.77,"timestamp":1765400400000,"preClose":0.7227,"halted":0,"volume":415099,"hourTrading":{"tag":"盘后","latestPrice":0.78,"preClose":0.77,"latestTime":"17:28 EST","volume":2693,"amount":2074.7123,"timestamp":1765405696199},"delay":0,"floatShares":20316700,"shares":42243774,"eps":-0.316036,"marketStatus":"Not Yet Opened","change":0.0473,"latestTime":"12-10 16:00:00 EST","open":0.725,"high":0.8,"low":0.7228,"amount":323169.00449223,"amplitude":0.106822,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.316036,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765443600000},"marketStatusCode":0,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":0.7227,"preHourTrading":{"tag":"盘前","latestPrice":0.7227,"preClose":0.7227,"latestTime":"09:26 EST","volume":787,"amount":569.06178788,"timestamp":1765376781583},"postHourTrading":{"tag":"盘后","latestPrice":0.78,"preClose":0.77,"latestTime":"17:28 EST","volume":2693,"amount":2074.7123,"timestamp":1765405696199},"volumeRatio":2.792139},"requestUrl":"/m/hq/s/RLYB","defaultTab":"news","newsList":[{"id":"2581020572","title":"Rallybio Corporation Reports Strong Q3 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020572","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020572?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:27","pubTimestamp":1762493244,"startTime":"0","endTime":"0","summary":"Rallybio Corporation ( ($RLYB) ) has released its Q3 earnings. Here is a breakdown of the information Rallybio Corporation presented to its investo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-corporation-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-corporation-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2581094614","title":"UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094614","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094614?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:35","pubTimestamp":1762439705,"startTime":"0","endTime":"0","summary":"Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 34.58 percent. This is a 46.15 percent increase over losses of $(0.26) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48687033/update-rallybio-q3-adj-eps-0-14-beats-0-21-estimate-sales-212-000k-beat-66-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB"],"gpt_icon":0},{"id":"2581509362","title":"Rallybio posts Q3 net income of $16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509362","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509362?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434223,"startTime":"0","endTime":"0","summary":"Rallybio Corporation reported a net income of $16.0 million, or $0.36 per common share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $0.26 per common share, for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $59.3 million. During the quarter, Rallybio generated $20.0 million from the sale of its interest in REV102 to Recursion Pharmaceuticals. The company advanced its lead program, RLYB116, with the completion of dosing in Cohort 1 of its confirmatory Phase 1 study, and expects to report data from the second cohort in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content us","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL807x3b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4609","BK4611","BK4548","RLYB","BK4139"],"gpt_icon":1},{"id":"2581098070","title":"BRIEF-Rallybio Q3 Net Income USD 16.016 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581098070","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581098070?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434047,"startTime":"0","endTime":"0","summary":"BRIEF-Rallybio Q3 Net Income USD 16.016 Million\n\n\nNov 06 (Reuters) - Rallybio Q3 operating expenses USD 7.137 million.\n\nQ3 income from operations USD -6.925 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX14905D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2581093253","title":"Rallybio Corp - Cash Runway Extended Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093253?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX14905D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2581093212","title":"Rallybio Corp -  Net Loss $0.36 per Common Share for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093212?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX14905D:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2578075627","title":"Rallybio’s RLYB116 Study: A Potential Game-Changer in Hematologic and Autoimmune Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578075627","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578075627?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:12","pubTimestamp":1761592334,"startTime":"0","endTime":"0","summary":"Rallybio Corporation (($RLYB)) announced an update on their ongoing clinical study. Rallybio Corporation is conducting a clinical study titled ‘Mul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybios-rlyb116-study-a-potential-game-changer-in-hematologic-and-autoimmune-disease-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybios-rlyb116-study-a-potential-game-changer-in-hematologic-and-autoimmune-disease-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2570702094","title":"Rallybio Completes Dosing of First Cohort in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2570702094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570702094?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:00","pubTimestamp":1758801646,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VC16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2570092887","title":"Rallybio Corp: Data Readouts for Completed Study Expected in 4Q 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2570092887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570092887?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:00","pubTimestamp":1758801646,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VC16J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RLYB","BK4139"],"gpt_icon":0},{"id":"2564398785","title":"Rallybio Receives $12.5 Million Equity Milestone Payment From Recursion for Advancement of REV102 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398785?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:01","pubTimestamp":1756900882,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UP12U:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2564398202","title":"Rallybio Corp  -","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398202?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:01","pubTimestamp":1756900882,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UP12U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RLYB","BK4139"],"gpt_icon":0},{"id":"2564398087","title":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398087?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:01","pubTimestamp":1756900871,"startTime":"0","endTime":"0","summary":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion. Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia . The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL767vCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4539","BK4139"],"gpt_icon":0},{"id":"2563071296","title":"Rallybio Corporation Faces Nasdaq Delisting Threat; Granted Extension to Regain Compliance with Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2563071296","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563071296?lang=en_us&edition=fundamental","pubTime":"2025-08-30 04:06","pubTimestamp":1756497970,"startTime":"0","endTime":"0","summary":"Rallybio Corporation Faces Nasdaq Delisting Threat; Granted Extension to Regain Compliance with Minimum Bid Price Requirement. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL28MCWq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2557682075","title":"Rallybio Q2 EPS $(0.22) Beats $(0.24) Estimate, Sales $212.000K Down From $299.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2557682075","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557682075?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:09","pubTimestamp":1754568599,"startTime":"0","endTime":"0","summary":"Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 10.2 percent. This is a 40.54 percent increase over losses of $(0.37) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46959482/rallybio-q2-eps-0-22-beats-0-24-estimate-sales-212-000k-down-from-299-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB"],"gpt_icon":0},{"id":"2557856872","title":"Rallybio Q2 revenue falls, net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2557856872","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557856872?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:09","pubTimestamp":1754568592,"startTime":"0","endTime":"0","summary":"Rallybio Q2 revenue falls, net loss narrowsOverviewRallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024Co sells REV102 interest for up to $2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX95E5C2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","RLYB"],"gpt_icon":1},{"id":"2557684975","title":"Rallybio Corp: Cash Runway Extended Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2557684975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557684975?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX95E5C2:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RLYB","BK4139"],"gpt_icon":0},{"id":"2557568547","title":"Rallybio Q2 Net Income USD -9.703 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2557568547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557568547?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX95E5C2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4539","BK4139"],"gpt_icon":0},{"id":"2557568300","title":"Rallybio Q2 Operating Expenses USD 10.269 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2557568300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557568300?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX95E5C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2550522050","title":"Sector Update: Health Care Stocks Advance in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2550522050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550522050?lang=en_us&edition=fundamental","pubTime":"2025-07-09 01:57","pubTimestamp":1751997449,"startTime":"0","endTime":"0","summary":"Health care stocks rose Tuesday afternoon with the NYSE Health Care Index gaining 0.3% and the Health Care Select Sector SPDR Fund  adding 0.5%.The iShares Biotechnology ETF  climbed 1.3%.In corporate news, Recursion Pharmaceuticals  shares jumped 11% after the company gained full rights to REV102, a drug candidate for hypophosphatasia, after acquiring Rallybio's  interest in the program. Rallybio surged 43%.Pfizer  Chief Corporate Officer Sally Susman will leave the company at the end of the year. Pfizer shares rose 1.1%.ProKidney  shares soared more than sixfold after the company said its investigational therapy rilparencel stabilized kidney function in a group of patients with chronic kidney disease and diabetes who received two injections about three months apart in a phase 2 trial, replicating the dosing regimen of its ongoing phase 3 study.Maze Therapeutics'  development strategy using genetic validation is seen as promising in terms of its target identification strategy and appl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","BK4592","IE00BBT3K403.USD","PFE.AU","BK4550","SG9999002232.USD","LU0306806265.USD","LU0985481810.HKD","BK4139","SG9999003800.SGD","LU0225771236.USD","IE00B19Z3B42.SGD","SG9999013999.USD","MAZE","LU0058720904.USD","SG9999001176.SGD","LU0868494617.USD","LU0321505439.SGD","LU1894683348.USD","LU1894683264.USD","IE00BLSP4452.SGD","LU1883839398.USD","SG9999002224.SGD","SG9999011175.SGD","LU1066053197.SGD","PROK","LU1023059063.AUD","BK4533","BK4581","LU1057294990.SGD","BK4534","LU0321505868.SGD","IBB","BK4588","BK4007","IE0002270589.USD","BK4539","XLV","IE00B19Z3581.USD","LU0170899867.USD","LU0289739699.SGD","LU1066051498.USD","RLYB","LU0456855351.SGD","LU0225284248.USD","RXRX","SG9999001176.USD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2549544605","title":"Rallybio Corporation Divests Interest in REV102 Program to Recursion Pharmaceuticals for Up to $25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544605","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544605?lang=en_us&edition=fundamental","pubTime":"2025-07-08 20:00","pubTimestamp":1751976038,"startTime":"0","endTime":"0","summary":"Rallybio Corporation has announced the sale of its interest in the REV102 program to Recursion Pharmaceuticals, a move anticipated to extend Rallybio's cash runway to mid-2027. The deal, valued at up to $25 million, includes an upfront equity payment of $7.5 million and additional milestone payments. The REV102 program, focused on developing an ENPP1 inhibitor for treating hypophosphatasia , originated from a joint venture between the two companies. Rallybio's CEO, Stephen Uden, expressed enthusiasm for the program's progression, highlighting the collaboration's success in advancing a potential oral disease-modifying treatment for HPP.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content us","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL1rRsmK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4548","RLYB","BK4609","BK4139","BK4539","BK4611"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.rallybio.com","stockEarnings":[{"period":"1week","weight":0.1667},{"period":"1month","weight":0.1848},{"period":"3month","weight":0.3016},{"period":"6month","weight":1.3765},{"period":"1year","weight":-0.3529},{"period":"ytd","weight":-0.1979}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.052117},{"month":2,"riseRate":0.5,"avgChangeRate":0.149998},{"month":3,"riseRate":0,"avgChangeRate":-0.234376},{"month":4,"riseRate":0.5,"avgChangeRate":-0.025587},{"month":5,"riseRate":0.5,"avgChangeRate":0.132316},{"month":6,"riseRate":0.25,"avgChangeRate":-0.189526},{"month":7,"riseRate":1,"avgChangeRate":0.176338},{"month":8,"riseRate":0.4,"avgChangeRate":-0.034234},{"month":9,"riseRate":0.6,"avgChangeRate":0.045433},{"month":10,"riseRate":0.6,"avgChangeRate":0.040053},{"month":11,"riseRate":0.2,"avgChangeRate":-0.230437},{"month":12,"riseRate":0.6,"avgChangeRate":0.027264}],"exchange":"NASDAQ","name":"Rallybio Corp.","nameEN":"Rallybio Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rallybio Corp.,RLYB,Rallybio Corp.股票,Rallybio Corp.股票老虎,Rallybio Corp.股票老虎国际,Rallybio Corp.行情,Rallybio Corp.股票行情,Rallybio Corp.股价,Rallybio Corp.股市,Rallybio Corp.股票价格,Rallybio Corp.股票交易,Rallybio Corp.股票购买,Rallybio Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}